Neurocrine Bio (NBIX) recently entered a deal with Abbott, which paid Neurocrine $75 million upfront, with the potential for another $500 million plus royalties still to come.
The partnership is a homerun in our view. Abbott is the ideal partner for Neurocrine with elagolix. The news comes less than a month after the phase II DAISY-901 program offered up positive data on all primary and secondary endpoints for the treatment of endometriosis.
We expect Abbott to be in position to initiate the phase III program on elagolix in endometriosis by the end of the year.Zacks Investment Research
